Coonoor polio vaccine unit to be closed

Coonoor Polio Vaccine Unit Closure — UPSC Study Note

1. At a Glance

• The oral polio vaccine (OPV) production unit at the Pasteur Institute of India (PII), Coonoor (Tamil Nadu) was shut down circa 1974 — a decision that stripped India of its only indigenous OPV manufacturing capacity for decades. [S3]
• The unit was an ICMR project operating within a state-managed institute, creating a classic dual-control governance failure. [S1]
• The closure is cited as a watershed moment in the decline of India's public-sector vaccine manufacturing infrastructure. [S2]
• UPSC relevance: intersects GS-II (health governance, ICMR, parliamentary oversight) and GS-III (biotechnology, public sector R&D).

2. Why in the News

• The article published in The Hindu (March 18, 2026) reproduces/highlights a historical dispatch dated New Delhi, March 17, reporting closure of the OPV unit at PII Coonoor effective March 31. [S1]
• The news resurfaces amid renewed debate on India's dependence on private/foreign vaccine manufacturers and the hollowing out of public-sector bio-manufacturing capacity. [S2]
• The Public Accounts Committee (PAC) of Lok Sabha had formally commented on the dysfunctional state of the unit, adding parliamentary accountability dimension. [S1]

3. Background & Evolution

4. Core Static Facts

• Institute name: Pasteur Institute of India (PII), Coonoor
• Location: Coonoor, Nilgiris district, Tamil Nadu
• Established: 1907
• Managing body: An Association (non-governmental management), with the OPV unit funded via Central grants routed through ICMR [S1]
• Vaccine produced: Trivalent Oral Polio Vaccine (OPV) — Sabin strain [S3]
• Parent ministry (OPV unit): Ministry of Health and Family Welfare (via ICMR) [S1]
• Batches released: 6 (1968–1974) [S3]
• Vaccine strain source: Donated by Albert Sabin in 1966 [S3]
• Parliamentary oversight body that flagged dysfunction: Public Accounts Committee (PAC), Lok Sabha [S1]
• Key governance defect: Dual control — OPV unit was ICMR project housed inside institute managed by a separate Association; created "lack of rapport between unit staff and Institute Director" [S1]
• Closure rationale: Technical expert opinion that reviving unit required "very heavy expenditure" with doubtful output quality [S1]
• Post-closure consequence: No Indian manufacturer produced OPV indigenously for decades thereafter [S3]

5. Multi-Dimensional Analysis

Scientific / Technological

• PII Coonoor was India's only indigenous OPV manufacturing site; its closure created a critical gap during the global polio eradication push. [S3]
• The unit had demonstrated technical viability (6 successful batches), making closure a policy failure, not a scientific one. [S3]
• India's failure to scale up in 1974 forced long-term dependence on imported or private-sector OPV, weakening vaccine sovereignty.

Administrative / Governance

• Dual-control structure — a recurring Indian public-sector failure: central funding (ICMR), but no central authority over institute staff (managed by Association). [S1]
• The PAC of Lok Sabha had flagged this as a "sorry state of affairs," yet no corrective action was taken — a classic case of audit findings not translating to executive action. [S1]
• A proposal to hand the institute to the Centre was floated but not acted upon promptly, illustrating inter-institutional inertia. [S1]

Economic

• Closure of a functional (albeit sub-optimal) public vaccine unit led to long-run import dependency costs and reduced bargaining power in vaccine procurement. [S2]
• Investment in reviving the unit was deemed too high by experts — but the long-term cost of non-revival was far greater in terms of National Immunisation Programme expenditure. [S3]

Social / Public Health

• India was a hyper-endemic country for polio until 2014 (certified polio-free). Loss of domestic OPV capacity during the most critical vaccination decades (1974–2000) affected programmatic immunization reach. [S3]
• Pulse Polio Immunisation (PPI) launched 1994–95 had to rely entirely on private and international suppliers; indigenous capacity could have reduced costs and supply-chain risks. [S3]

Legal / Constitutional

• The OPV unit operated under Central grants via ICMR; the parent institute was under a private Association — creating ambiguity in accountability under Article 12 (definition of "State" for fundamental rights obligations). [S1]
• The move to hand over PII to the Centre would have required legislative/administrative steps aligning with Seventh Schedule (Union List Entry 26: pharmaceutical standards). [S1]

Historical

• Mirrors the broader pattern of India building public-sector vaccine institutions in the colonial/early independence era (CRI Kasauli 1905, PII Coonoor 1907, BCG Lab Chennai 1948) and then allowing them to decay through under-investment and governance neglect. [S2]
• Repeated licence suspensions (2008–10) of the same trio of public-sector labs confirms the structural rot was never addressed. [S3]

6. Recent Developments (Last 12–18 Months)

• March 2026: The Hindu republishes/highlights the historical article on OPV unit closure, prompting renewed discussion on public-sector vaccine manufacturing revival. [S1]
• India's vaccine self-reliance discourse has intensified post-COVID-19 (Atmanirbhar Bharat in pharma); the Coonoor case is cited as a cautionary historical precedent. [S2]
• 2008–2010 licence suspension of PII Coonoor (along with CRI Kasauli and BCG Lab Chennai) for Good Manufacturing Practice (GMP) non-compliance was revoked in February 2010 to safeguard vaccine security. [S3]

7. Prelims Hooks

1. The Pasteur Institute of India, Coonoor was established in 1907 — prompted by a hydrophobia death in 1902. [S4]
2. PII Coonoor is located in the Nilgiris district, Tamil Nadu. [S4]
3. Albert Sabin donated OPV strains to PII Coonoor in 1966 and personally trained institute staff. [S3]
4. PII Coonoor released 6 batches of OPV between 1968 and 1974 under Veeraraghavan and Balasubramanian. [S3]
5. The OPV production unit was funded via Central grants routed through ICMR (not directly by the Health Ministry). [S1]
6. The Public Accounts Committee (PAC) of Lok Sabha formally commented on the dysfunctional state of the OPV unit. [S1]
7. The key governance defect cited was "dual control" — ICMR project inside an Association-managed institute. [S1]
8. After PII Coonoor's OPV unit closed (~1974), no Indian manufacturer produced OPV indigenously for decades. [S3]
9. WHO launched the Expanded Programme on Immunization (EPI) globally in 1974 — the same year India shut its only OPV unit. [S3]
10. In 2008, the government suspended manufacturing licences of three public-sector vaccine labs: PII Coonoor, CRI Kasauli, and BCG Vaccine Laboratory, Chennai. [S3]
11. Licences of the above three labs were restored in February 2010 in "larger public interest of vaccine security." [S3]
12. PII Coonoor also developed India's first indigenous trivalent OPV and conducted research on Vero cell-derived rabies vaccine. [S4]
13. National Institute of Nutrition (NIN), part of ICMR, traces its origins to Beri-Beri research at PII Coonoor. [S4]
14. The implementing ministry for the OPV unit was the Ministry of Health and Family Welfare (via ICMR). [S1]

8. Mains Relevance

• GS-II: Governance — Issues relating to development and management of social sector (health); role of Parliament (PAC oversight); functioning of autonomous bodies under Central grants.
• GS-III: Science & Technology — Indigenization of technology; biotechnology; India's pharmaceutical self-reliance; public-sector R&D institutions.

Plausible Mains question stems: 1. "The closure of the OPV unit at Pasteur Institute of India, Coonoor in the 1970s exemplifies the governance pathologies that have plagued India's public-sector vaccine manufacturing. Critically examine." (GS-II) 2. "India's journey to becoming polio-free by 2014 was a public health triumph, yet it was achieved despite — not because of — its indigenous vaccine manufacturing capacity. Discuss with reference to Pulse Polio Immunisation and institutional factors." (GS-II/III) 3. "How has dual-control of central-grant projects housed in state/autonomous institutions impeded India's science and technology infrastructure? Illustrate with examples." (GS-II)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Confusing PII Coonoor with CRI Kasauli: Both are colonial-era public vaccine labs, but CRI Kasauli (est. 1905, Himachal Pradesh) makes different vaccines; PII Coonoor (est. 1907, Tamil Nadu) was the OPV site. Different states, different products.
2. Assuming ICMR directly managed the institute: ICMR provided Central grants to the OPV unit, but the Pasteur Institute itself was managed by an Association — the dual-control tension arose precisely from this split.
3. Attributing closure to scientific failure: The closure was a governance and funding decision, not a technical one — experts noted the unit had produced acceptable vaccine; the issue was cost of revival and institutional dysfunction.
4. Wrong closure date: The OPV unit closure happened circa 1974 (after 6 batches, 1968–74); a separate licence suspension occurred in 2008 (revoked 2010) — these are two distinct events frequently conflated.
5. Confusing OPV (Sabin) with IPV (Salk): The PII unit produced Oral Polio Vaccine (OPV) — the Sabin strain administered orally; not the Injectable Polio Vaccine (IPV/Salk strain), which India later introduced under UIP from 2015.

11. Sources

• [S1] "Coonoor polio vaccine unit to be closed" — The Hindu (March 18, 2026, archival article dated New Delhi, March 17) — https://www.thehindu.com/todays-paper/2026-03-18/th_international/articleGBRFNSNL6-13898819.ece — (Tier 4; primary article)
• [S2] "How India faltered and frittered away its 'vaccine' expertise built since 1850" — National Herald India — https://www.nationalheraldindia.com/india/how-india-faltered-and-frittered-away-its-vaccine-expertise-built-since-1850 — (Tier 4)
• [S3] "A brief history of vaccines & vaccination in India" / "Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status" — ICMR / Indian Journal of Medical Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC4078488/ ; https://ijmr.org.in/eradicating-poliomyelitis-indias-journey-from-hyperendemic-to-polio-free-status/ — (Tier 3)
• [S4] "Pasteur Institute of India" — Wikipedia / Pasteur Institute of India official site — https://en.wikipedia.org/wiki/Pasteur_Institute_of_India ; https://www.pasteurinstituteindia.com/pasteur-institute-of-india/ — (Reference)